![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Bibliography
- Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011;11(3):450-62
- Eckberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitor in renal transplantation. New Engl J Med 2007;357(25):2562-75
- Flechner SM, Glyda M, Cockfield S, et al. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011;11(8):1633-44
- Budde K, Lehner F, Sommerer C, et al. Conversion form cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study. Am J Transplant 2012;12(6):1528-40
- Arora S, Tangirala B, Osaschuk L, Sureshkumar KK. Belatacept: a new biological agent for maintenance immunosuppression in kidney transplantation. Expert Opin Biol Ther 2012;12(7):965-79
- Yamda A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol 13:559-75.2002
- Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT Study). Am J Transplant 2010;10(3):535-46
- Durrback A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplant from extended criteria donors (BENEFIT-EXT Study). Am J Transplant 2010;10(3):547-57
- Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005;353:770-81
- Rostaing L, Neumayer HH, Reyes-Acevedo R, et al. Belatacept-versus Cyclosporine-based immuposuppresion in renal transplant recipients with pre-existing diabetes. Clin J Am Soc Nephrol 2011;6:2696-704
- Florman S, Bresnahan B, Chan L, et al. Three year outcomes in black/African American kidney transplant recipients from BENEFIT and BENEFIT-EXT studies. Am Transplant Congress 2011;11:abstract 1091
- Schnitzler MA, Kalsekar A, L’Italien G, et al. Use of 12-month renal function and baseline clinical factors to predict long-term graft survival: application to BENEFIT and BENEFIT-EXT trials. Transplantation 2012;93(2):172-81
- Ferguson R, Grinyo J, Vincenti F, et al. Immunosuppresion with Belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant 2011;11:66-76
- Rostaing L, Vincenti F, Grinyo J, et al. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT Study. Am J Transplant 2013;13:2875-83
- Charpentier B, Medina Pestana JO, Rial M del C, et al. Long-term exposure to belatacept in recipients of extended criteria donor kidneys. Am J Transplant 2013;13:2884-91
- Rostaing L, Massari P, Garcia VD, et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol 2011;6:430-9
- Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a randomized, active controlled, parallel group study in adult kidney transplant recipients. Am J Transplant 2012;12:210-17
- Riella LV, Sayegh MH. T-cell co-stimulatory blockade in transplantation: two steps forward one step back!. Expert Opin Biol Ther 2013;13(11):1557-68